Gastric Cancer - Pipeline Review, H1 2015
Summary
Global Markets Directs, Gastric Cancer - Pipeline Review, H1 2015, provides an overview of the Gastric Cancers therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Gastric Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA ), route of administration (RoA ) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Gastric Cancer and special features on late-stage and discontinued projects.
Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides a snapshot of the global therapeutic landscape of Gastric Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Gastric Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Gastric Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Gastric Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products
Reasons to buy
- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Gastric Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Gastric Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents 2
Introduction 7
Gastric Cancer Overview 8
Therapeutics Development 9
Gastric Cancer - Therapeutics under Development by Companies 11
Gastric Cancer - Therapeutics under Investigation by Universities/Institutes 21
Gastric Cancer - Pipeline Products Glance 23
Gastric Cancer - Products under Development by Companies 27
Gastric Cancer - Products under Investigation by Universities/Institutes 39
Gastric Cancer - Companies Involved in Therapeutics Development 40
Gastric Cancer - Therapeutics Assessment 144
Drug Profiles 164
Gastric Cancer - Recent Pipeline Updates 456
Gastric Cancer - Dormant Projects 595
Gastric Cancer - Discontinued Products 603
Gastric Cancer - Product Development Milestones 606
Appendix 613
List Of Tables
Number of Products under Development for Gastric Cancer, H1 2015 28
Number of Products under Development for Gastric Cancer - Comparative Analysis, H1 2015 29
Number of Products under Development by Companies, H1 2015 31
Number of Products under Development by Companies, H1 2015 (Contd..1 ) 32
Number of Products under Development by Companies, H1 2015 (Contd..2 ) 33
Number of Products under Development by Companies, H1 2015 (Contd..3 ) 34
Number of Products under Development by Companies, H1 2015 (Contd..4 ) 35
Number of Products under Development by Companies, H1 2015 (Contd..5 ) 36
Number of Products under Development by Companies, H1 2015 (Contd..6 ) 37
Number of Products under Development by Companies, H1 2015 (Contd..7 ) 38
Number of Products under Development by Companies, H1 2015 (Contd..8 ) 39
Number of Products under Investigation by Universities/Institutes, H1 2015 41
Comparative Analysis by Late Stage Development, H1 2015 42
Comparative Analysis by Clinical Stage Development, H1 2015 43
Comparative Analysis by Early Stage Development, H1 2015 44
Comparative Analysis by Unknown Stage Development, H1 2015 45
Products under Development by Companies, H1 2015 46
Products under Development by Companies, H1 2015 (Contd..1 ) 47
Products under Development by Companies, H1 2015 (Contd..2 ) 48
Products under Development by Companies, H1 2015 (Contd..3 ) 49
Products under Development by Companies, H1 2015 (Contd..4 ) 50
Products under Development by Companies, H1 2015 (Contd..5 ) 51
Products under Development by Companies, H1 2015 (Contd..6 ) 52
Products under Development by Companies, H1 2015 (Contd..7 ) 53
Products under Development by Companies, H1 2015 (Contd..8 ) 54
Products under Development by Companies, H1 2015 (Contd..9 ) 55
Products under Development by Companies, H1 2015 (Contd..10 ) 56
Products under Development by Companies, H1 2015 (Contd..11 ) 57
Products under Investigation by Universities/Institutes, H1 2015 58
Gastric Cancer - Pipeline by AB Science, H1 2015 59
Gastric Cancer - Pipeline by AbbVie Inc., H1 2015 60
Gastric Cancer - Pipeline by AbGenomics International, Inc., H1 2015 61
Gastric Cancer - Pipeline by Advaxis, Inc., H1 2015 62
Gastric Cancer - Pipeline by Advenchen Laboratories, LLC, H1 2015 63
Gastric Cancer - Pipeline by Ambrx, Inc., H1 2015 64
Gastric Cancer - Pipeline by Amgen Inc., H1 2015 65
Gastric Cancer - Pipeline by Aslan Pharmaceuticals Pte. Ltd., H1 2015 66
Gastric Cancer - Pipeline by Astellas Pharma Inc., H1 2015 67
Gastric Cancer - Pipeline by AstraZeneca PLC, H1 2015 68
Gastric Cancer - Pipeline by AVEO Pharmaceuticals, Inc., H1 2015 69
Gastric Cancer - Pipeline by Avipep Pty Ltd, H1 2015 70
Gastric Cancer - Pipeline by Azaya Therapeutics Incorporated, H1 2015 71
Gastric Cancer - Pipeline by Basilea Pharmaceutica AG, H1 2015 72
Gastric Cancer - Pipeline by Bayer AG, H1 2015 73
Gastric Cancer - Pipeline by Bellicum Pharmaceuticals, Inc., H1 2015 74
Gastric Cancer - Pipeline by BioMarin Pharmaceutical Inc., H1 2015 75
Gastric Cancer - Pipeline by Biotecnol, Inc., H1 2015 76
Gastric Cancer - Pipeline by Boehringer Ingelheim GmbH, H1 2015 77
Gastric Cancer - Pipeline by Boston Biomedical, Inc., H1 2015 78
Gastric Cancer - Pipeline by Bristol-Myers Squibb Company, H1 2015 79
Gastric Cancer - Pipeline by cCAM Biotherapeutics Ltd., H1 2015 80
Gastric Cancer - Pipeline by Celgene Corporation, H1 2015 81
Gastric Cancer - Pipeline by Cellectar Biosciences, Inc., H1 2015 82
Gastric Cancer - Pipeline by Celltrion, Inc., H1 2015 83
Gastric Cancer - Pipeline by Celon Pharma Sp. z o.o., H1 2015 84
Gastric Cancer - Pipeline by Cerulean Pharma, Inc., H1 2015 85
Gastric Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2015 86
Gastric Cancer - Pipeline by Chugai Pharmaceutical Co., Ltd., H1 2015 87
Gastric Cancer - Pipeline by Covagen AG, H1 2015 88
Gastric Cancer - Pipeline by DAE HWA Pharmaceutical Co., Ltd., H1 2015 89
Gastric Cancer - Pipeline by Daiichi Sankyo Company, Limited, H1 2015 90
Gastric Cancer - Pipeline by Deciphera Pharmaceuticals, LLC, H1 2015 91
Gastric Cancer - Pipeline by DiaMedica Inc., H1 2015 92
Gastric Cancer - Pipeline by Dong-A Socio Group, H1 2015 93
Gastric Cancer - Pipeline by Eddingpharm, H1 2015 94
Gastric Cancer - Pipeline by Eli Lilly and Company, H1 2015 95
Gastric Cancer - Pipeline by Epirus Biopharmaceuticals, Inc., H1 2015 96
Gastric Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H1 2015 97
Gastric Cancer - Pipeline by Exelixis, Inc., H1 2015 98
Gastric Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H1 2015 99
Gastric Cancer - Pipeline by Five Prime Therapeutics, Inc., H1 2015 100
Gastric Cancer - Pipeline by Galaxy Biotech, LLC, H1 2015 101
Gastric Cancer - Pipeline by Galena Biopharma, Inc., H1 2015 102
Gastric Cancer - Pipeline by Genentech, Inc., H1 2015 103
Gastric Cancer - Pipeline by GlaxoSmithKline plc, H1 2015 104
Gastric Cancer - Pipeline by GlycoNex Inc., H1 2015 105
Gastric Cancer - Pipeline by Glycotope GmbH, H1 2015 106
Gastric Cancer - Pipeline by Green Cross Corporation, H1 2015 107
Gastric Cancer - Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H1 2015 108
Gastric Cancer - Pipeline by Hutchison MediPharma Limited, H1 2015 109
Gastric Cancer - Pipeline by ImmunoGen, Inc., H1 2015 110
Gastric Cancer - Pipeline by Immunomedics, Inc., H1 2015 111
Gastric Cancer - Pipeline by Imugene Limited, H1 2015 112
Gastric Cancer - Pipeline by Incuron, LLC, H1 2015 113
Gastric Cancer - Pipeline by Incyte Corporation, H1 2015 114
Gastric Cancer - Pipeline by INSYS Therapeutics, Inc., H1 2015 115
Gastric Cancer - Pipeline by Intezyne, Inc, H1 2015 116
Gastric Cancer - Pipeline by ISU ABXIS Co.,Ltd., H1 2015 117
Gastric Cancer - Pipeline by Jiangsu Hengrui Medicine Co., Ltd., H1 2015 118
Gastric Cancer - Pipeline by Jiangsu Kanion Pharmaceutical Co., Ltd., H1 2015 119
Gastric Cancer - Pipeline by Kadmon Corporation, LLC, H1 2015 120
Gastric Cancer - Pipeline by Karyopharm Therapeutics, Inc., H1 2015 121
Gastric Cancer - Pipeline by Kinex Pharmaceuticals, LLC, H1 2015 122
Gastric Cancer - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2015 123
Gastric Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H1 2015 124
Gastric Cancer - Pipeline by Les Laboratoires Servier SAS, H1 2015 125
Gastric Cancer - Pipeline by MacroGenics, Inc., H1 2015 126
Gastric Cancer - Pipeline by Mebiopharm Co., Ltd., H1 2015 127
Gastric Cancer - Pipeline by Merck & Co., Inc., H1 2015 128
Gastric Cancer - Pipeline by Merck KGaA, H1 2015 129
Gastric Cancer - Pipeline by Mersana Therapeutics, Inc., H1 2015 130
Gastric Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H1 2015 131
Gastric Cancer - Pipeline by Molecular Targeting Technologies, Inc., H1 2015 132
Gastric Cancer - Pipeline by MSM Protein Technologies, Inc., H1 2015 133
Gastric Cancer - Pipeline by NanoCarrier Co., Ltd., H1 2015 134
Gastric Cancer - Pipeline by NeoPharm Co., Ltd., H1 2015 135
Gastric Cancer - Pipeline by Novartis AG, H1 2015 136
Gastric Cancer - Pipeline by Omnitura Therapeutics Inc., H1 2015 137
Gastric Cancer - Pipeline by OncoTherapy Science, Inc., H1 2015 138
Gastric Cancer - Pipeline by Oncothyreon Inc., H1 2015 139
Gastric Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H1 2015 140
Gastric Cancer - Pipeline by Panacea Biotec Limited, H1 2015 141
Gastric Cancer - Pipeline by Patrys Limited, H1 2015 142
Gastric Cancer - Pipeline by Pfizer Inc., H1 2015 143
Gastric Cancer - Pipeline by Pharmacyclics, Inc., H1 2015 144
Gastric Cancer - Pipeline by Priaxon AG, H1 2015 145
Gastric Cancer - Pipeline by Regulon Inc., H1 2015 146
Gastric Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H1 2015 147
Gastric Cancer - Pipeline by Richter Gedeon Nyrt., H1 2015 148
Gastric Cancer - Pipeline by Sanofi, H1 2015 149
Gastric Cancer - Pipeline by Sareum Holdings plc, H1 2015 150
Gastric Cancer - Pipeline by SentoClone International AB, H1 2015 151
Gastric Cancer - Pipeline by Sequella, Inc., H1 2015 152
Gastric Cancer - Pipeline by Siena Biotech S.p.A., H1 2015 153
Gastric Cancer - Pipeline by Sorrento Therapeutics, Inc., H1 2015 154
Gastric Cancer - Pipeline by Sunesis Pharmaceuticals, Inc., H1 2015 155
Gastric Cancer - Pipeline by Supratek Pharma Inc., H1 2015 156
Gastric Cancer - Pipeline by Synta Pharmaceuticals Corp., H1 2015 157
Gastric Cancer - Pipeline by Synthon Holdings BV, H1 2015 158
Gastric Cancer - Pipeline by Taiho Pharmaceutical Co., Ltd., H1 2015 159
Gastric Cancer - Pipeline by Tesaro, Inc., H1 2015 160
Gastric Cancer - Pipeline by Vaxon Biotech, H1 2015 161
Gastric Cancer - Pipeline by Zymeworks Inc., H1 2015 162
Assessment by Monotherapy Products, H1 2015 163
Assessment by Combination Products, H1 2015 164
Number of Products by Stage and Target, H1 2015 166
Number of Products by Stage and Mechanism of Action, H1 2015 174
Number of Products by Stage and Route of Administration, H1 2015 180
Number of Products by Stage and Molecule Type, H1 2015 182
Gastric Cancer Therapeutics - Recent Pipeline Updates, H1 2015 475
Gastric Cancer - Dormant Projects, H1 2015 614
Gastric Cancer - Dormant Projects (Contd..1 ), H1 2015 615
Gastric Cancer - Dormant Projects (Contd..2 ), H1 2015 616
Gastric Cancer - Dormant Projects (Contd..3 ), H1 2015 617
Gastric Cancer - Dormant Projects (Contd..4 ), H1 2015 618
Gastric Cancer - Dormant Projects (Contd..5 ), H1 2015 619
Gastric Cancer - Dormant Projects (Contd..6 ), H1 2015 620
Gastric Cancer - Dormant Projects (Contd..7 ), H1 2015 621
Gastric Cancer - Discontinued Products, H1 2015 622
Gastric Cancer - Discontinued Products (Contd..1 ), H1 2015 623
Gastric Cancer - Discontinued Products (Contd..2 ), H1 2015 624
List Of Figures
List of Figures
Number of Products under Development for Gastric Cancer, H1 2015 28
Number of Products under Development for Gastric Cancer - Comparative Analysis, H1 2015 29
Number of Products under Development by Companies, H1 2015 30
Number of Products under Investigation by Universities/Institutes, H1 2015 40
Comparative Analysis by Late Stage Development, H1 2015 42
Comparative Analysis by Clinical Stage Development, H1 2015 43
Comparative Analysis by Early Stage Products, H1 2015 44
Assessment by Monotherapy Products, H1 2015 163
Assessment by Combination Products, H1 2015 164
Number of Products by Stage and Top 10 Targets, H1 2015 165
Number of Products by Top 10 Mechanism of Actions, H1 2015 173
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 173
Number of Products by Top 10 Routes of Administration, H1 2015 179
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 179
Number of Products by Top 10 Molecule Types, H1 2015 181
Number of Products by Stage and Top 10 Molecule Types, H1 2015 181
